Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily lonafarnib with ritonavir for chronic hepatitis D
MOH_2021-02-16_009766Phase 3Not yet recruiting
- Sponsor
- דר אוהד עציון
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lonafarnib and ritonavir in Chronic Viral Hepatitis B With Delta-Agent, sponsored by דר אוהד עציון. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
lonafarnibritonavir
03
Conditions
Chronic Viral Hepatitis B With Delta-Agent
Beyond the preview
Go deeper on MOH_2021-02-16_009766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-16_009766.